Characterizing SOD1 mutations in Spain: The impact of genotype, age and sex in the natural history of the disease
Vázquez-Costa, J.F.; Borrego-Hernández, D.; Paradas, C.; Gómez-Caravaca, M.T.; Rojas-Garcia, R.; Varona, L.; Povedano, M.; García-Sobrino, T.; Jericó Pascual, I.; Gutiérrez, A.; Riancho, J.; Turon-Sans, J.; Assialioui, A.; Pérez-Tur, J.; Sevilla, T.; Esteban Pérez, J.; García-Redondo, A.; López, A.A.; Calabria, M.D.; Díaz-Marín, C.; Caravaca, E.F.; Dávila, L.G.; Martínez, A.G.; Gimenez-Muñoz, Á.; Sola, A.G.; Cadavid, J.M.; Mora Pardina, J.S.; Blanco, J.L.M.; Juntas-Morales, R.; Morgado, Y.; Pardo Fernández, Julio; Valladares, A.; Vilar-Ventura, R.M.

Identificadores
Identificadores
Visualización ou descarga de ficheiros
Visualización ou descarga de ficheiros
Data de publicación
2023Título da revista
European Journal of Neurology
Tipo de contido
Artigo
Resumo
Background and purpose: The aim of this study was to describe the frequency and distribution of SOD1 mutations in Spain, and to explore factors contributing to their phenotype and prognosis. Methods: Seventeen centres shared data on amyotrophic lateral sclerosis (ALS) patients carrying pathogenic or likely pathogenic SOD1 variants. Multivariable models were used to explore prognostic modifiers. Results: In 144 patients (from 88 families), 29 mutations (26 missense, 2 deletion/insertion and 1 frameshift) were found in all five exons of SOD1, including seven novel mutations. A total of 2.6% of ALS patients (including 17.7% familial and 1.3% sporadic) were estimated to carry SOD1 mutations. The frequency of this mutation varied considerably among regions, due to founder events. The most frequent mutation was p.Gly38Arg (n = 58), followed by p.Glu22Gly (n = 11), p.Asn140His (n = 10), and the novel p.Leu120Val (n = 10). Most mutations were characterized by a protracted course, and some of them by atypical phenotypes. Older age of onset was independently associated with faster disease progression (exp[Estimate] = 1.03 [0.01, 0.05], p = 0.001) and poorer survival (hazard ratio 1.05 [1.01, 1.08], p = 0.007), regardless of the underlying mutation. Female sex was independently associated with faster disease progression (exp[Estimate] = 2.1 [1.23, 3.65], p = 0.012) in patients carrying the p.Gly38Arg mutation, resulting in shorter survival compared with male carriers (236 vs. 301 months). Conclusions: These data may help to evaluate the efficacy of SOD1 targeted treatments, and to expand the number of patients that might benefit from these treatments.
A non ser que se indique outra cousa, a licenza do ítem descríbese comoAttribution-NonCommercial-NoDerivatives 4.0 International
